Met-enkephalin-like immunoreactivity in neurointermediate pituitary is decreased by DA receptor stimulation.
The effect of dopamine receptor stimulation by administration of the dopamine analogue bromocriptine on Met-enkephalin-LI was examined in rat hypothalamus, and neurointermediate and anterior lobes of pituitary. Bromocriptine treatment resulted in a dramatic decline of Met-enkephalin-LI in neurointermediate pituitary which was significant by 3 days of treatment. Maximal reduction of Met-enkephalin-LI ranged between 60-70% of pretreatment values and was maintained as long as bromocriptine was administered (4 weeks), with no evidence of desensitization or "escape." The effects of bromocriptine on neurointermediate lobe were of long duration and persisted for at least 4 days after discontinuation of treatment. No significant effects of bromocriptine were detected on Met-enkephalin-LI in hypothalamus or anterior pituitary. Whether these differences represent truly different regional regulation of Met-enkephalin-LI or whether the changes are more sensitively reflected in an area such as neurointermediate lobe that largely consists of nerve terminals, remains to be shown.
D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology*; D004744:Enkephalin, Methionine / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology*; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors
D011954:Receptors, Dopamine; D001971:Bromocriptine; D004744:Enkephalin, Methionine; D006220:Haloperidol